Norway’s Clavis Pharma ASA Signs $380 Million Cancer Drug Deal with Clovis Oncology (JOBS)

Reuters -- Norwegian pharmaceutical company Clavis Pharma said on Tuesday it had signed a cancer drug development deal worth around $380 million with U.S.-based Clovis Oncology, boosting its shares as much as 86 percent.